Q1 2022 Results
Company overview
Financial performance
CRM
Immunology
Financial review
Neuroscience
2022 priorities
Innovation: Pipeline overview
Ophthalmology
Appendix
Innovation: Clinical trials
Respiratory & Allergy
Oncology: Solid Tumors
References
Abbreviations
Hematology
Biosimilars
Global Health
MIJ821- NR2B negative allosteric modulator (NAM)
Study
Indication
Phase
Patients
Primary Outcome
Measures
Arms Intervention
NCT04722666 (CMIJ821A12201)
Major depressive disorder with acute suicidal ideation or behavior
Phase 2
195
Change from baseline to 24 hours in the total score of the Montgomery Åsberg
Depression Rating Scale (MADRS)
MIJ821 (mg/kg) very low dose for 40 minutes IV infusion on Day 1, Day 15 and Day 29
MIJ821 (mg/kg) low dose for 40 minutes IV infusion on Day 1, Day 15 and Day 29
MIJ821 (mg/kg) high dose for 40 minutes IV infusion on Day 1, Day 15 and Day 29
MIJ821 (mg/kg) very high dose for 40 minutes IV infusion on Day 1, Day 15 and Day 29
Placebo 40 minutes IV infusion of 0.9% sodium chloride on Day 1, Day 15 and Day 29
MIJ821 (mg/kg) high dose for 40 minutes IV infusion on Day 1 or 0.9% sodium chloride
Participants who have suicidal ideation with intent
Target Patients
Read-out Milestone(s)
Publication
2023
TBD
70 Investor Relations | Q1 2022 Results
1 NOVARTIS | Reimagining MedicineView entire presentation